Majumdar Selected to Serve on NIH Center for Scientific Review Study Section
Published on 07 October 2020
Susruta Majumdar, Ph.D., associate professor of medicinal chemistry at University of Health Sciences and Pharmacy in St. Louis, has been selected to serve on the National Institutes of Health (NIH) Center for Scientific Review Drug Discovery for the Nervous System Study Section (DDNS).
In his new role, Majumdar will review and make recommendations on grant applications submitted to NIH, score them and help decide which applications are worthy of NIH funding. As part of the DDNS Study Section, Majumdar will review grant proposals related to research on the central nervous system and focused on topics such as anxiety, depression, addiction, analgesia and Alzheimer’s disease.
NIH Study Section members are selected based on their demonstrated competence and achievement in their scientific discipline as evidenced by the quality of their personal research accomplishments, publications in scientific journals and other significant scientific activities, achievements and honors.
Majumdar was chosen based on his expertise in chemistry and pharmacology, as well as his extensive catalog of research publications focused on the chemical biology of opioid receptors and his previous ad-hoc work to review grant applications for NIH’s Helping to End Addiction Long-term (HEAL) Initiative aimed at creating scientific solutions to stem the national opioid public health crisis.
He will serve a four-year term on the DDNS Study Section, taking part in two-day grant review sessions each February, June and October.
“This is an exciting appointment for me because of the impact this type of service can have on the scientific community,” Majumdar said. “If I see a good idea from a colleague of mine, I have the opportunity to push that idea forward. I also get the chance to support the novel ideas of young investigators who need funding from NIH to support their work. Those that are getting started in research need the advice of their more experienced peers, and this study section is a mechanism for me to support their ideas.”
As a member of the DDNS Study Section, Majumdar says he also has the ability to provide critical feedback to investigators on their grant applications.
“Being chosen for a study section gives validation to the research work I’ve done and offers me the opportunity to evaluate the work of others,” Majumdar noted. “I can make suggestions on ways investigators can make their work more compelling. This is important because very often investigators take the advice and put in work to improve their applications. The better the application, the more likely it is to get funded in the future.”
With Majumdar’s appointment to the DDNS Study Section having the potential to shape the future of research, it represents a new milestone in his research career and also marks a significant milestone for University of Health Sciences and Pharmacy in St. Louis as it continues to gain a reputation for groundbreaking research and innovation. During 2019, the University was ranked No. 1 in NIH funding among private pharmacy schools in the U.S.
“My service with the DDNS Study Section is a good thing for the University because it demonstrates that we are serious about academic discovery,” Majumdar explained. “And because the study section is focused on grants related to the central nervous system, my service is also great for the Center for Clinical Pharmacology, which is located on our campus. Researchers from the Center are focused on drug discovery related to the central nervous system, and their grant proposals go to the DDNS Study Section. My service will allow me to coach our researchers on how to market, sell and fine-tune their ideas, and develop grant applications that have a good shot at getting funded.”
To learn more about the NIH Center for Scientific Review Study Sections, visit public.csr.nih.gov.